| scholarly article | Q13442814 |
| P50 | author | Ian H. Gilbert | Q38322743 |
| Paul G. Wyatt | Q41782047 | ||
| Ruth Brenk | Q50638394 | ||
| P2093 | author name string | Daniel James | |
| Alessandro Schipani | |||
| Julie Frearson | |||
| Agata Krasowski | |||
| P2860 | cites work | Hit and lead generation: beyond high-throughput screening | Q28204526 |
| Drug development for neglected diseases: a deficient market and a public-health policy failure | Q28207953 | ||
| Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches | Q28290933 | ||
| Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings | Q28842973 | ||
| The art and practice of structure-based drug design: A molecular modeling perspective | Q29029768 | ||
| Drugs for bad bugs: confronting the challenges of antibacterial discovery | Q29547723 | ||
| Protein kinases--the major drug targets of the twenty-first century? | Q29615339 | ||
| Can the pharmaceutical industry reduce attrition rates? | Q29616077 | ||
| Opportunities and Challenges in Antiparasitic Drug Discovery | Q29999214 | ||
| Pursuing the leadlikeness concept in pharmaceutical research. | Q30832332 | ||
| A novel approach to combinatorial library design | Q30833119 | ||
| Property distribution of drug-related chemical databases. | Q30855791 | ||
| Molecular complexity and its impact on the probability of finding leads for drug discovery | Q30993107 | ||
| Is there a difference between leads and drugs? A historical perspective | Q31017131 | ||
| A fresh look at pharmaceutical screening library design | Q31154316 | ||
| A new approach to finding natural chemical structure classes | Q33185162 | ||
| Drug-like annotation and duplicate analysis of a 23-supplier chemical database totalling 2.7 million compounds | Q33199870 | ||
| "In-house likeness": comparison of large compound collections using artificial neural networks | Q33220365 | ||
| Recent developments in focused library design: targeting gene-families | Q33232966 | ||
| Relationships between Molecular Complexity, Biological Activity, and Structural Diversity | Q33237552 | ||
| An empirical process for the design of high-throughput screening deck filters. | Q33244050 | ||
| Virtual ligand screening: strategies, perspectives and limitations | Q33247681 | ||
| Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening | Q33267859 | ||
| High-throughput screening affords novel and selective trypanothione reductase inhibitors with anti-trypanosomal activity | Q33267962 | ||
| A high-throughput screening approach to anthrax lethal factor inhibition | Q33275326 | ||
| Identifying druglike inhibitors of myelin-reactive T cells by phenotypic high-throughput screening of a small-molecule library | Q33283649 | ||
| On sampling of fragment space | Q33287567 | ||
| A ‘Rule of Three’ for fragment-based lead discovery? | Q33973131 | ||
| In silico approaches to prediction of aqueous and DMSO solubility of drug-like compounds: trends, problems and solutions | Q34493552 | ||
| Protein kinases as drug targets in trypanosomes and Leishmania | Q34578463 | ||
| Two decades of orphan product development | Q34932215 | ||
| Integration of virtual and high-throughput screening | Q34988235 | ||
| Designing screens: how to make your hits a hit. | Q35096198 | ||
| Targeting metabolic pathways in microbial pathogens: oxidative stress and anti-folate drug resistance in trypanosomatids | Q35139370 | ||
| A journey of hope: lessons learned from studies on rare diseases and orphan drugs | Q36514274 | ||
| Innovative lead discovery strategies for tropical diseases | Q36642049 | ||
| Drug discovery and development for neglected parasitic diseases | Q36654913 | ||
| Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors | Q36723753 | ||
| A decade of fragment-based drug design: strategic advances and lessons learned | Q36732253 | ||
| How many leads from HTS? | Q56627226 | ||
| Strategic Pooling of Compounds for High-Throughput Screening | Q56854153 | ||
| Patent sense | Q60099865 | ||
| Database diversity assessment: new ideas, concepts, and tools | Q73913472 | ||
| Virtual exploration of the small-molecule chemical universe below 160 Daltons | Q81327462 | ||
| Virtual Exploration of the Small-Molecule Chemical Universe below 160 Daltons | Q99234037 | ||
| P433 | issue | 3 | |
| P921 | main subject | drug discovery | Q1418791 |
| drug screening | Q10505555 | ||
| P304 | page(s) | 435-444 | |
| P577 | publication date | 2008-03-01 | |
| P1433 | published in | ChemMedChem | Q2962252 |
| P1476 | title | Lessons learnt from assembling screening libraries for drug discovery for neglected diseases | |
| P478 | volume | 3 |
| Q64964051 | 5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma. |
| Q27678978 | A Novel Allosteric Inhibitor of the Uridine Diphosphate N -Acetylglucosamine Pyrophosphorylase from Trypanosoma brucei |
| Q35837029 | A Screenable In Vivo Assay for Mitochondrial Modulators Using Transgenic Bioluminescent Caenorhabditis elegans. |
| Q35839906 | A Substrate Mimic Allows High-Throughput Assay of the FabA Protein and Consequently the Identification of a Novel Inhibitor of Pseudomonas aeruginosa FabA |
| Q30044020 | A novel multiple-stage antimalarial agent that inhibits protein synthesis |
| Q34153687 | A physicochemical descriptor-based scoring scheme for effective and rapid filtering of kinase-like chemical space |
| Q27902327 | A reliable computational workflow for the selection of optimal screening libraries |
| Q39003990 | Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need |
| Q52641243 | Apoptotic impact on Brugia malayi by sulphonamido-quinoxaline: search for a novel therapeutic rationale. |
| Q90194262 | Application of the SwissDrugDesign Online Resources in Virtual Screening |
| Q36227748 | Applications of Systematic Molecular Scaffold Enumeration to Enrich Structure-Activity Relationship Information |
| Q114969995 | AutoGrow4: an open-source genetic algorithm for de novo drug design and lead optimization |
| Q39811801 | Bioreductively activated lysyl oxidase inhibitors against hypoxic tumours |
| Q38028557 | Cell-based apoptosis assays in oncology drug discovery |
| Q57190987 | Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis |
| Q37405261 | Combinatorial chemistry: oh what a decade or two can do. |
| Q38966911 | Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay |
| Q51775733 | Comparison of structure- and ligand-based virtual screening protocols considering hit list complementarity and enrichment factors. |
| Q93112180 | Computational advances in combating colloidal aggregation in drug discovery |
| Q26997089 | Computational methods in drug discovery |
| Q90448352 | Constrained Bayesian optimization for automatic chemical design using variational autoencoders |
| Q27677088 | De Novo Design of Protein Kinase Inhibitors by in Silico Identification of Hinge Region-Binding Fragments |
| Q33494087 | Design of chemical libraries with potentially bioactive molecules applying a maximum common substructure concept |
| Q28548536 | Development and Validation of a Novel Leishmania donovani Screening Cascade for High-Throughput Screening Using a Novel Axenic Assay with High Predictivity of Leishmanicidal Intracellular Activity. |
| Q35784017 | Development of Small-Molecule Trypanosoma brucei N-Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode. |
| Q38919697 | Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi |
| Q35791902 | Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei |
| Q35779255 | Discovery of Inhibitors of Trypanosoma brucei by Phenotypic Screening of a Focused Protein Kinase Library |
| Q27676019 | Discovery of a Novel Class of Orally Active Trypanocidal N -Myristoyltransferase Inhibitors |
| Q37412029 | Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy |
| Q27679901 | Discovery of an Allosteric Inhibitor Binding Site in 3-Oxo-acyl-ACP Reductase from Pseudomonas aeruginosa |
| Q38135446 | Drug discovery for neglected diseases: molecular target-based and phenotypic approaches |
| Q37866927 | Drug repositioning for orphan diseases |
| Q35604907 | FAF-Drugs3: a web server for compound property calculation and chemical library design. |
| Q38823016 | Fragment screening reveals salicylic hydroxamic acid as an inhibitor of Trypanosoma brucei GPI GlcNAc-PI de-N-acetylase. |
| Q34775438 | From on-target to off-target activity: identification and optimisation of Trypanosoma brucei GSK3 inhibitors and their characterisation as anti-Trypanosoma brucei drug discovery lead molecules |
| Q33621193 | HTS and hit finding in academia--from chemical genomics to drug discovery |
| Q33696424 | High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules |
| Q64062708 | Identification of a potential allosteric site of Golgi α-mannosidase II using computer-aided drug design |
| Q33653056 | Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis |
| Q46667725 | Identification of dual Acetyl-CoA carboxylases 1 and 2 inhibitors by pharmacophore based virtual screening and molecular docking approach. |
| Q88131729 | Identification of inhibitors of an unconventional Trypanosoma brucei kinetochore kinase. |
| Q38948559 | Identification of inhibitors of the Leishmania cdc2-related protein kinase CRK3. |
| Q35301222 | Identification of small molecule inhibitors of pre-mRNA splicing |
| Q60049273 | In silico identification and experimental validation of hits active against KPC-2 β-lactamase |
| Q64072132 | In silico structural elucidation of RNA-dependent RNA polymerase towards the identification of potential Crimean-Congo Hemorrhagic Fever Virus inhibitors |
| Q60948280 | In vitro antiplasmodial activity, pharmacokinetic profiles and interference in isoprenoid pathway of 2-aniline-3-hydroxy-1.4-naphthoquinone derivatives |
| Q35531225 | In vitro screening for drug repositioning |
| Q41896284 | Increasing the coverage of medicinal chemistry-relevant space in commercial fragments screening. |
| Q92702959 | Inhibition of Oncogenic Kinases: An In Vitro Validated Computational Approach Identified Potential Multi-Target Anticancer Compounds |
| Q37037229 | Innovation in academic chemical screening: filling the gaps in chemical biology |
| Q30897674 | Investigation of trypanothione reductase as a drug target in Trypanosoma brucei |
| Q28483059 | IspE inhibitors identified by a combination of in silico and in vitro high-throughput screening |
| Q38737293 | Kallikrein-related peptidases (KLKs) and the hallmarks of cancer |
| Q112623136 | KnowTox: pipeline and case study for confident prediction of potential toxic effects of compounds in early phases of development |
| Q34604133 | Locating sweet spots for screening hits and evaluating pan-assay interference filters from the performance analysis of two lead-like libraries |
| Q34041986 | Mining the ChEMBL database: an efficient chemoinformatics workflow for assembling an ion channel-focused screening library |
| Q90650657 | Multitarget Drug Design, Molecular Docking and PLIF Studies of Novel Tacrine-Coumarin Hybrids for the Treatment of Alzheimer's Disease |
| Q28550655 | Multivariate PLS Modeling of Apicomplexan FabD-Ligand Interaction Space for Mapping Target-Specific Chemical Space and Pharmacophore Fingerprints |
| Q24594745 | N-myristoyltransferase inhibitors as new leads to treat sleeping sickness |
| Q64121987 | New flavonoid – N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties |
| Q26863285 | Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects |
| Q27667324 | Novel Ligands for a Purine Riboswitch Discovered by RNA-Ligand Docking |
| Q89429231 | On-Chip Screening of a Glycomimetic Library with C-Type Lectins Reveals Structural Features Responsible for Preferential Binding of Dectin-2 over DC-SIGN/R and Langerin |
| Q27655956 | One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening |
| Q33667540 | Overcoming scientific and structural bottlenecks in antibacterial discovery and development |
| Q92288313 | Phenoxyethyl Piperidine/Morpholine Derivatives as PAS and CAS Inhibitors of Cholinesterases: Insights for Future Drug Design |
| Q55372049 | Phytochemical analysis and docking study of compounds present in a polyherbal preparation used in the treatment of dermatophytosis. |
| Q91344605 | Potential Inhibitors of Galactofuranosyltransferase 2 (GlfT2): Molecular Docking, 3D-QSAR, and In Silico ADMETox Studies |
| Q89414823 | QEX: target-specific druglikeness filter enhances ligand-based virtual screening |
| Q42414958 | Quantifying the chemical beauty of drugs. |
| Q28303907 | Rational methods for the selection of diverse screening compounds |
| Q47162276 | Screening a protein kinase inhibitor library against Plasmodium falciparum |
| Q27684822 | Screening-based discovery ofAspergillus fumigatusplant-type chitinase inhibitors |
| Q35878687 | Selecting, Acquiring, and Using Small Molecule Libraries for High-Throughput Screening |
| Q37852737 | State of the art in African trypanosome drug discovery |
| Q93333339 | Structurally unique PARP-1 inhibitors for the treatment of prostate cancer |
| Q58919960 | Structure-Based Virtual Screening and Molecular Dynamic Simulation Studies to Identify Novel Cytochromebc1Inhibitors as Antimalarial Agents |
| Q37356679 | Structure-based ligand design and the promise held for antiprotozoan drug discovery. |
| Q39001919 | Studies of genotoxicity and mutagenicity of nitroimidazoles: demystifying this critical relationship with the nitro group. |
| Q42318665 | SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules |
| Q37449692 | Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter |
| Q64067149 | TeachOpenCADD: a teaching platform for computer-aided drug design using open source packages and data |
| Q28584450 | The ChEMBL database in 2017 |
| Q37101499 | Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials |
| Q90914855 | Unpacking the Pathogen Box-An Open Source Tool for Fighting Neglected Tropical Disease |
Search more.